In breast cancer cells, the chemotherapeutic agent doxorubicin had a dual effect on PD-L1 expression: it was effective in downregulating the cell surface expression of PD-L1, but it also showed an upregulation of this molecule in the nucleus. This evidence concerns the gene CD274 and breast carcinoma.